Nesfatin-1

Dosing from the Literature

Published for fat loss: animal research doses only, injected into rodents. Not published: any human dose; no one has been dosed in a trial.

Nesfatin-1 has no validated human dose in any indication because no exogenous-administration clinical studies have been conducted. The dosing frameworks below are preclinical animal research doses, presented for research context only.

What It Is

Nesfatin-1 is an endogenous 82-amino-acid peptide processed from the N-terminus of the 396-amino-acid precursor protein nucleobindin-2 (NUCB2, historically known as NEFA). The precursor is cleaved at a prohormone-convertase site to generate three potential fragments: nesfatin-1 (AA 1–82, biologically active), nesfatin-2, and nesfatin-3 (both of unknown physiological function). The molecule was named for "NEFA/nucleobindin-2-encoded satiety and fat-influencing protein" and identified in 2006 by Oh-I, Shimizu, Mori and colleagues at Gunma University in a targeted screen for novel hypothalamic (brain's hormonal control center) appetite-regulating molecules. Their landmark Nature paper (443:709-712, PMID 17036007) demonstrated that (a) intracerebroventricular injection of NUCB2 or nesfatin-1 in rats decreased food intake in a dose-dependent manner, (b) only the nesfatin-1 fragment produced the satiety effect — other NUCB2 fragments did not, (c) antisense morpholino knockdown of endogenous NUCB2 produced weight gain, and (d) the anorexigenic action was preserved in leptin-receptor-deficient Zucker rats, establishing independence from the leptin pathway.

Anatomically, NUCB2/nesfatin-1 is expressed in hypothalamic appetite-regulating nuclei — the paraventricular nucleus (PVN), supraoptic nucleus (SON), arcuate nucleus (ARC), lateral hypothalamic area (LHA), and the nucleus of the solitary tract (NTS) in the brainstem. Extensive colocalization has been documented with oxytocin (~40%), vasopressin (~50%), α-MSH (the hormone that tells skin to tan) / POMC (~60–80%), melanin-concentrating hormone (~80%), urocortin-1 (~90%), CART, corticotropin-releasing factor, and thyrotropin-releasing hormone (Stengel 2013 review; Kohno 2008). This pleiotropic (having many effects at once) neuroanatomy underpins nesfatin-1's role as a regulator not just of food intake but also of stress response, cardiovascular tone, glucose homeostasis, reproductive function, and anxiety.

Peripherally, NUCB2/nesfatin-1 is produced in gastric X/A-like endocrine cells, pancreatic β-cells, adipose tissue, and testes. Circulating levels rise postprandially in some contexts and are altered in obesity, type 2 diabetes, PCOS, metabolic syndrome, anorexia nervosa, inflammatory bowel disease, and several cardiovascular conditions — making NUCB2/nesfatin-1 a widely-studied biomarker in human metabolic and endocrine disease even in the complete absence of therapeutic use.

Twenty years after discovery, nesfatin-1 has not entered clinical development. The reasons are pharmacologically straightforward: an 82-amino-acid peptide (~9.7 kDa) is not a drug-like size for routine parenteral dosing, its central mechanism makes blood–brain barrier penetration a critical unknown for peripheral administration, and downstream actions on the better-developed oxytocin–POMC–MC4R (the receptor that controls appetite) pathway are more readily accessed through the tractable melanocortin-4 receptor agonist drug class (setmelanotide, etc.). Nesfatin-1 remains a compelling endogenous regulatory peptide and a valuable research tool, but not a near-term therapeutic.

Mechanism of Action

• Leptin-independent anorexia — Nesfatin-1-induced anorexia is preserved in leptin-receptor-deficient Zucker rats, and anti-nesfatin-1 antibody does not block leptin-induced anorexia. These observations established leptin-independence at the time of discovery (Oh-I 2006, PMID 17036007).
• Oxytocin–POMC–melanocortin pathway — Nesfatin-1 directly depolarizes oxytocin neurons in the PVN (Maejima 2009). PVN oxytocin neurons project to POMC neurons in the NTS, which release α-MSH that engages MC3R (a melanocortin receptor for energy balance)/MC4R. Pharmacologic blockade of the oxytocin receptor or MC3R/MC4R abolishes nesfatin-1 anorexia (Yosten 2010, PMID 20335376) — providing a clean mechanism-of-action trace.
• Melanocortin dependence — Centrally administered α-MSH elevates NUCB2 gene expression in PVN; an MC3/4R antagonist blocks nesfatin-1 satiety (Oh-I 2006). Places nesfatin-1 upstream in a hypothalamic melanocortin cascade with tight reciprocal regulation.
• Dorsal vagal complex — Nesfatin-1 modulates glucosensing neurons in the DVC, increasing firing of glucose-excited neurons and decreasing firing of glucose-inhibited neurons. This brainstem site contributes to anorexia alongside the hypothalamic limb (Dong 2014, PMC4048226).
• Peripheral glucose regulation — Pancreatic β-cell NUCB2/nesfatin-1 exhibits glucose-dependent insulinotropic action; exogenous nesfatin-1 stimulates fatty-acid oxidation by activating AMPK in skeletal muscle and liver in STZ-induced T2D mouse models, improving glucose tolerance (Yang 2013, PMC3877039).
• Blood–brain barrier permeation — Nesfatin-1 crosses the BBB in both directions by non-saturable mechanisms (Pan 2007), raising the theoretical possibility of peripheral delivery reaching central targets — though the practical efficiency of peripheral-to-central delivery for an 82 AA peptide is limited.
• Central cardiovascular pressor effect — ICV nesfatin-1 produces a pressor response in rats via a CRH–oxytocin–melanocortin central autonomic circuit; nesfatin-1 is therefore not a "clean" anorexigenic — autonomic effects accompany the satiety signal (Yosten & Samson 2014, PMID 24598461).
• Anxiogenic / anxiolytic effects (context-dependent) — Central administration has produced both anxiogenic and anxiolytic signals in different rodent paradigms; the net effect depends on dose, route, and anatomical target.
• Stress and feeding coupling — NUCB2/nesfatin-1 neurons are activated by stressors and refeeding; the peptide sits at an intersection of stress-related HPA output and energy balance (Kohno 2008).
• Pleiotropy — Colocalization with urocortin-1, MCH, POMC, vasopressin, oxytocin, NPY, CRF, TRH, GHRH (the signal that tells the pituitary to release GH) provides a neuroanatomical basis for pleiotropic actions on energy balance, stress, reproductive, and cardiovascular regulation (Stengel review; Foo et al.).
• Middle segment M30 is the active fragment — Proteolytic dissection studies suggest that a ~30-amino-acid middle segment of nesfatin-1 (M30) retains the anorexigenic activity of the full 82-amino-acid peptide. M30 is shorter than full nesfatin-1 and has been used as a research-tool fragment to interrogate structure–activity relationships within the molecule.
• Reproductive-axis engagement — García-Galiano and colleagues (2010) demonstrated nesfatin-1 modulation of hypothalamic–pituitary–gonadal (HPG) axis function in rodents, including modulation of luteinizing-hormone release. This reproductive-axis limb is proposed as a substrate for observed NUCB2/nesfatin-1 alterations in polycystic ovary syndrome cohorts.
• Adipose-tissue expression — Ramanjaneya and colleagues (2010, Endocrinology) documented NUCB2/nesfatin-1 expression in human and murine adipose tissue with depot-specific elevation in obesity, positioning the peptide as an adipokine in addition to its central/enteric roles.
• Cardioprotection (preclinical) — Animal ischemia-reperfusion models suggest nesfatin-1 has cardioprotective properties through modulation of apoptotic and oxidative-stress pathways in cardiomyocytes. Mechanistic data only; not translated.
• Anxiety paradigms — Context-dependent anxiogenic and anxiolytic signals in rodent elevated-plus-maze, forced-swim, and social-interaction tests. Net behavioral effect depends on dose, route, and anatomical target.
• Gastric secretion / motility — Enteric nesfatin-1 expression in gastric X/A-like cells co-localizes with ghrelin; the two peptides have reciprocal effects on appetite (ghrelin orexigenic, nesfatin-1 anorexigenic) and may represent a bidirectional satiety-hunger control system at the peripheral level.

What the Research Shows

Nesfatin-1 literature is voluminous (thousands of papers since 2006) and dominated by animal-model mechanism studies plus human biomarker correlations.

• Discovery paper — Oh-I 2006 (PMID 17036007, Nature) — Identified nesfatin-1 as the biologically active fragment of NUCB2. ICV injection produced dose-dependent anorexia; antibody neutralization increased appetite; antisense knockdown produced weight gain. Anorexia preserved in leptin-receptor-deficient rats (leptin-independent).
• Oxytocin-dependence — Yosten & Samson 2010 (PMID 20335376) — Pretreatment with oxytocin receptor antagonist abolishes nesfatin-1 anorexia and hypertensive effects. Established the OT-neuron-mediated central pathway.
• Melanocortin-pathway mapping — Maejima 2009 (Cell Metab) — Nesfatin-1-induced activation of PVN oxytocin neurons projects to POMC neurons in NTS, producing melanocortin-mediated anorexia independent of leptin.
• Stengel minireview — 2011 (PMID 21862618) — Canonical review framing NUCB2/nesfatin-1 as an emerging player in the brain–gut, endocrine, and metabolic axis.
• Peripheral glucose regulation — Yang 2013 (PMC3877039) — Nesfatin-1 activates AMPK in skeletal muscle and liver, stimulates fatty-acid oxidation, improves glucose tolerance in STZ-induced diabetic mice.
• Dorsal vagal complex glucosensing — Dong 2014 (PMC4048226) — Nesfatin-1 excites glucose-excited neurons and inhibits glucose-inhibited neurons in DVC; brainstem contribution to anorexia.
• BBB permeation — Pan 2007 — Non-saturable bidirectional transport across BBB.
• Cardiovascular / pressor — Yosten & Samson 2014 (PMID 24598461) — Central hypertensive action of nesfatin-1 through melanocortin, CRH, oxytocin circuitry.
• Biomarker — obesity and T2DM — Multiple studies report altered circulating NUCB2/nesfatin-1 in obesity, T2DM, metabolic syndrome (reviews by Stengel, Taché; Aydin).
• Biomarker — anorexia nervosa and restrictive eating — Altered levels in AN and restrictive-eating patients; suggestive of regulatory-signal dysfunction but not therapeutic target.
• Biomarker — polycystic ovary syndrome — Elevated circulating NUCB2/nesfatin-1 documented in PCOS cohorts.
• Central ischemic stroke signal (preclinical) — Some preclinical data suggest neuroprotective effects in cerebral ischemia models; early-stage.
• Reproductive endocrinology — Nesfatin-1 engages hypothalamic–pituitary–gonadal axis in rodents; modulates LH and reproductive function.
• Anxiety paradigms — Context-dependent anxiogenic/anxiolytic signals; elevated plus maze and forced-swim results vary by dose and route.

Human Data

• No exogenous-administration trials — No published clinical trial has administered synthetic nesfatin-1 to human subjects for therapeutic purposes.
• Human biomarker studies — obesity — Multiple cross-sectional studies documenting altered circulating NUCB2/nesfatin-1 levels in adults and children with obesity.
• Human biomarker studies — type 2 diabetes — Elevated or reduced circulating levels in T2D depending on cohort and fasting/fed state; relationship is complex.
• Human biomarker studies — anorexia nervosa — Altered levels in patients with AN and in recovering patients; proposed as a biomarker of restrictive eating.
• Human biomarker studies — PCOS — Elevated levels in PCOS cohorts in multiple studies.
• Human biomarker studies — sleep apnea, hypertension, CV disease — Associations reported in multiple cohorts; directionally inconsistent across studies.
• Human biomarker studies — pregnancy — Nesfatin-1 levels altered across gestation, suggestive of roles in gestational metabolic adaptation and possibly in gestational diabetes.
• Genetic / GWAS — NUCB2 variants associated with obesity risk in some candidate-gene studies; not replicated in large-scale GWAS to the same degree as leptin or MC4R.
• Reproductive endocrinology — Altered levels in reproductive-axis disorders; not therapeutic target data.
• No Phase 1 / 2 / 3 trial registrations — ClinicalTrials.gov and WHO ICTRP searches as of April 2026 return no active or completed interventional trials administering exogenous nesfatin-1 to humans.

Reconstitution & Storage

Nesfatin-1 is supplied as a lyophilized powder for research use, typically in 100 µg or 1 mg vial sizes for peptide-grade research reagent. It is not formulated for human administration.

No label or guideline gives a storage condition or shelf life for nesfatin-1; it is sold as a research reagent. The table is arithmetic only: what a vial of a given size holds once dissolved. It is not a recommendation, and no study has given the peptide to a person.

→ Calculator — vial-to-syringe math

Side Effects & Risks

• Unknown in humans — No controlled human safety data exists for exogenous nesfatin-1 administration.
• Theoretical anxiogenic signal — Rodent paradigms show context-dependent anxiogenic and anxiolytic responses; direction uncertain in humans.
• Theoretical central pressor effect — Rodent ICV administration produces hypertensive responses via CRH–oxytocin–melanocortin circuitry (Yosten & Samson 2014). Peripheral administration at therapeutic doses would need to clear this as a safety signal.
• Theoretical HPA-axis activation — Colocalization with CRF neurons and activation by stressors suggests potential HPA-axis effects with chronic administration.
• Theoretical reproductive endocrine effects — Modulation of the HPG axis in rodents makes it a theoretical concern for people of reproductive age.
• Theoretical glucose-regulatory effects — Pancreatic β-cell effects and muscle AMPK activation could produce clinically meaningful glucose or insulin shifts with chronic administration.
• BBB delivery uncertainty — For peripheral administration, the degree to which the peptide reaches central targets in therapeutically meaningful quantities is not established in humans.
• Contraindications (theoretical) — Its pharmacologic profile makes pregnancy, lactation, uncontrolled hypertension, active eating disorder and HPA-axis dysfunction theoretical contraindications.
• Product purity — Research-grade peptide purity is not regulated to pharmaceutical standards; contamination risk is real.
• Long-term safety — Not characterized in any organism beyond short-term rodent experiments.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for nesfatin-1, and no study has given it to a person. The rodent studies measured food intake, body weight, blood pressure, glucose and insulin; the human studies measured circulating NUCB2/nesfatin-1 by ELISA (see Human Data).

Commonly Stacked With

No study has given nesfatin-1 with another compound. The adjacent biology below is what the published work connects it to.

• Melanocortin-4 receptor — The terminal effector of nesfatin-1's anorexigenic cascade is MC4R. Setmelanotide, the FDA-approved MC4R agonist, is the regulatorily tractable version of nesfatin-1's downstream signal for rare monogenic obesity (POMC deficiency, LEPR deficiency, Bardet-Biedl syndrome).
• Oxytocin — Central oxytocin signaling is required for nesfatin-1 anorexia. Intranasal oxytocin has been evaluated for feeding-behavior modulation in Prader-Willi syndrome and obesity; clinical data is mixed.
• Pancreatic β-cell biology — Nesfatin-1 is produced in β-cells and has glucose-dependent insulinotropic activity, placing it in the same biology as GLP-1 and GIP. This is the mechanistic substrate connecting nesfatin-1 research to the broader incretin / β-cell-protection field.
• Stress-feeding coupling — The colocalization of NUCB2/nesfatin-1 with CRF and urocortin in the PVN illustrates the neuroanatomical integration of stress and feeding. Stress-related eating disorders may involve this circuitry.
• Reproductive endocrinology — NUCB2 variants and altered circulating nesfatin-1 in PCOS suggest involvement in reproductive-axis pathology. Clinical relevance evolving.
• Biomarker potential — Most clinical interest in nesfatin-1 as of 2026 is as a biomarker of energy-balance dysregulation rather than as a therapeutic target — reflecting the practical challenges of administering an 82 AA peptide with uncertain CNS penetration.
• Lifestyle interventions for energy balance — The validated interventions for weight reduction remain caloric deficit, increased physical activity, sleep optimization, and (where indicated) pharmacotherapy with approved GLP-1 RAs, GLP-1/GIP dual agonists, or MC4R agonists in rare monogenic disease.

Stacking this? Read the receipt →

Research Timeline — Twenty Years of Nesfatin-1

For context in evaluating nesfatin-1's therapeutic trajectory, the following summarizes key milestones:

• 2006 — Discovery — Oh-I et al. identify nesfatin-1 as a novel hypothalamic satiety molecule (Nature, PMID 17036007).
• 2008 — Colocalization mapping — Kohno et al. document extensive overlap with oxytocin, vasopressin, POMC, CART, α-MSH, and other appetite regulators.
• 2009 — Mechanism definition — Maejima et al. (Cell Metab) establish the oxytocin → POMC → α-MSH → MC3R/4R downstream cascade.
• 2010 — Oxytocin-dependence — Yosten & Samson demonstrate oxytocin-receptor-antagonist reversal of nesfatin-1 anorexia (PMID 20335376).
• 2011 — Canonical review — Stengel & Taché minireview framing nesfatin-1 in the brain–gut–endocrine axis (PMID 21862618).
• 2013 — Peripheral glucose regulation — Yang et al. document AMPK activation and fatty-acid oxidation in STZ-T2D mice.
• 2014 — DVC mechanism — Dong et al. map glucosensing-neuron modulation in the dorsal vagal complex; central-cardiovascular pressor circuit (Yosten & Samson).
• 2015–2020 — Biomarker expansion — Cross-sectional studies in obesity, T2D, PCOS, anorexia nervosa, sleep apnea, cardiovascular disease, pregnancy, inflammatory conditions.
• 2020–2026 — Therapeutic development stasis — No IND-stage program has advanced exogenous nesfatin-1 toward human trials. Adjacent regulatorily-tractable targets (setmelanotide for MC4R; GLP-1 RAs; oxytocin) have become the clinically translated versions of the nesfatin-1 mechanism.

Legal Status

Related Compounds

People researching Nesfatin-1 often also look at these:

Next Steps

References

1. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-712. PMID: 17036007.
2. Stengel A, Goebel M, Wang L, Taché Y. Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight. Peptides. 2010;31(2):357-369. PMID: 19944123.
3. Stengel A, Taché Y. Minireview: Nesfatin-1 — an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology. 2011;152(11):4033-4038. PMID: 21862618.
4. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1642-R1647. PMID: 20335376.
5. Yosten GL, Samson WK. Neural circuitry underlying the central hypertensive action of nesfatin-1: melanocortins, corticotropin-releasing hormone, and oxytocin. Am J Physiol Regul Integr Comp Physiol. 2014;306(10):R722-R727. PMID: 24598461.
6. Maejima Y, Sedbazar U, Suyama S, Kohno D, Onaka T, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, Tanaka S, Dezaki K, Oh-I S, Hashimoto K, Shimizu H, Nakata M, Mori M, Yada T. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab. 2009;10(5):355-365. PMID: 19883614.
7. Kohno D, Nakata M, Maejima Y, Shimizu H, Sedbazar U, Yoshida N, Dezaki K, Onaka T, Mori M, Yada T. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology. 2008;149(3):1295-1301. PMID: 18048495.
8. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides. 2007;28(11):2223-2228. PMID: 17950952.
9. Dong J, Xu H, Xu H, Wang PF, Cai GJ, Song HF, Wang CC, Dong ZT, Ju YJ, Jiang ZY. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One. 2013;8(12):e83397. PMID: 24391760.
10. Dong J, Xu H, Wang PF, Cai GJ, Song HF, Wang CC, Dong ZT, Ju YJ, Jiang ZY. Nesfatin-1 influences the excitability of glucosensing neurons in the dorsal vagal complex and inhibits food intake. PLoS One. 2014;9(6):e98966. PMID: 24906120.
11. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol. 2010;45(5):281-290. PMID: 20682642.
12. Goebel-Stengel M, Wang L. Central and peripheral expression and distribution of NUCB2/nesfatin-1. Curr Pharm Des. 2013;19(39):6935-6940. PMID: 23537079.
13. Stengel A, Taché Y. Role of brain NUCB2/nesfatin-1 in the regulation of food intake. Curr Pharm Des. 2013;19(39):6955-6959. PMID: 23537088.
14. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010;151(7):3169-3180. PMID: 20427481.
15. Aydin S. Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine. 2013;44(2):312-325. PMID: 23526235.
16. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
17. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S0, Non-approved substances. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Read October 3, 2026.

Related Research

• KisspeptinEndogenous HPG Axis Master Regulator
• 5-Amino-1MQNNMT Inhibitor
• AdipotideExperimental Pro-Apoptotic Chimera
• AICARAMPK Activator / Exercise Mimetic
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.